Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
End‐stage liver fibrosis frequently progresses to portal vein thrombosis, formation of oesophageal varices, hepatic encephalopathy, ascites, hepatocellular carcinoma and liver failure. Mesenchymal stem cells (MSCs), when transplanted in vivo, migrate into fibrogenic livers and then differentiate into hepatocyte‐like cells or fuse with hepatocytes to protect liver function. Moreover, they can produce various growth factors and cytokines with anti‐inflammatory effects to reverse the fibrotic state of the liver. In addition, only a small number of MSCs migrate to the injured tissue after cell transplantation; consequently, multiple studies have investigated effective strategies to improve the survival rate and activity of MSCs for the treatment of liver fibrosis. In this review, we intend to arrange and analyse the current evidence related to MSC transplantation in liver fibrosis, to summarize the detailed mechanisms of MSC transplantation for the reversal of liver fibrosis and to discuss new strategies for this treatment. Finally, and most importantly, we will identify the current problems with MSC‐based therapies to repair liver fibrosis that must be addressed in order to develop safer and more effective routes for MSC transplantation. In this way, it will soon be possible to significantly improve the therapeutic effects of MSC transplantation for liver regeneration, as well as enhance the quality of life and prolong the survival time of patients with liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363 · cited 1×
“The secretome is a special set of factors (soluble proteins, free nucleic acids, lipids and extracellular vesicles) secreted into the extracellular space and changes in response to fluctuations in various conditions.(42) Cell‐free secretome isolated from MSCs exerted antifibrotic effects by inhibiting activation of TG…”
BackgroundZhang, Z., Lin, H., Shi, M., Xu, R., Fu, J., Lv, J., Chen, L., Lv, S., Li, Y., Yu, S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07024.x · Cited by 372 · cited 1×
“After one year, MSC transfusion proved to be clinically safe and effectively reduced ascites in these patients.(79) Conversely, Fang et al enrolled 103 HBV‐induced decompensated liver cirrhosis recently and showed that MSC transplantation significantly decreased the serum levels of IL‐6, TNF‐α, T8 cells and B cells, b…”
BackgroundSuk, K. T., Yoon, J., Kim, M. Y., Kim, C. W., Kim, J. K., Park, H., Hwang, S. G., Kim, D. J., Lee, B. S., Lee, S. H., et al. (2016) · Hepatology · doi:10.1002/hep.28693 · Cited by 303 · cited 1×
“In addition, 72 patients with alcoholic cirrhosis were enrolled for MSC transplantation, and although one‐time and two‐time transplantation reduced collagen deposition by 25% and 37%, respectively, there was no significant difference in fibrosis quantification between the two groups.(83) MSC transplantation has been d…”
BackgroundHuang, B., Cheng, X., Wang, H., Huang, W., la Ga hu, Z., Wang, D., Zhang, K., Zhang, H., Xue, Z., Da, Y., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0792-1 · Cited by 183
El-Ansary, M., Abdel-Aziz, I., Mogawer, S., Abdel-Hamid, S., Hammam, O., Teaema, S., & Wahdan, M. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9322-y · Cited by 179 · cited 1×
“In addition, 25 patients with Child C grade HCV‐induced liver cirrhosis underwent MSC transplantation and hepatogenic MSC transplantation (approximately 40% hepatocyte‐like cells and 60% MSCs), both treatments up‐regulated the levels of prothrombin and albumin while down‐regulating the levels of bilirubin and MELD sco…”
BackgroundMicroencapsulated human mesenchymal stem cells decrease liver fibrosis in mice
Meier, R. P. H., Mahou, R., Morel, P., Meyer, J., Montanari, E., Muller, Y. D., Christofilopoulos, P., Wandrey, C., Gonelle-Gispert, C., & Bühler, L. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.030 · Cited by 153
Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis
Zhao, W. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i10.1048 · Cited by 140
The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases
Liu, W., Song, F., Ren, L., Guo, W., Wang, T., Feng, Y., Tang, L., & Li, K. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12482 · Cited by 139 · cited 1×
“Mesenchymal stem cells migrate into fibrogenic liver tissues after transplantation in vivo and then differentiate into hepatocyte‐like cells or fuse with hepatocytes to protect liver function.(13) Interestingly, Park et al previously showed that human palatine tonsil‐ derived MSCs responded only to disease tissue, as…”
BackgroundLiang, J., Zhang, H., Zhao, C., Wang, D., Ma, X., Zhao, S., Wang, S., Niu, L., & Sun, L. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13015 · Cited by 93 · cited 1×
“Liang et al enrolled 26 patients with autoimmune disease‐induced liver cirrhosis and observed beneficial effects on liver function after infusions of MSCs via peripheral veins with no serious adverse effects.(86) Zhang enrolled 60 patients with hepatolenticular degeneration‐induced liver fibrosis and demonstrated that…”
Background
Cited by
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 270
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“Recently, Lin et al. suggested a therapeutic strategy by targeting leukocyte-derived chemotaxis 2/tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domain (LECT2/Tie1) signaling with bevacizumab (anti-VEGF/VEGFR signaling) to reverse fibrosis [199,216,217].”
BackgroundAlternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
Tricot, T., De Boeck, J., & Verfaillie, C. (2020) · Cells · doi:10.3390/cells9030566 · Cited by 20
“In addition, undifferentiated MSCs may ameliorate liver fibrosis [76], even if there are also reports suggesting that they may aggravate fibrogenesis [81,84], making the case for in vitro differentiation prior to transplantation.”
BackgroundJiang, C., Chen, H., Kang, Y., He, X., Huang, J., Lu, T., Sui, X., Chen, H., Xiao, J., Zhang, J., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01546-3 · Cited by 15
Cell therapy for end-stage liver disease: Current state and clinical challenge
Zhang, L., Deng, Y., Bai, X., Wei, X., Ren, Y., Chen, S., & Deng, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003332 · Cited by 12
“[144] When sufficient evidence is present to illustrate the predictive value of these human biomimetic liver microphysiology system models for efficacy and toxicity data, it is expected to replace animal studies with human 3D in vitro liver tissue models.”
Metadata
- Authors
- Hu, C., Zhao, L., Duan, J., & Li, L.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2019-01-11
- Volume
- 23
- Issue
- 3
- Pages
- 1657-1670
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2908954957
- Cited by
- 77
- References
- 15
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.